Genialis
Boston, US · Founded 2015 · Delaware corporation · 32 employees on LinkedIn · 6 known investors
Find your way into Genialis
268 people in our graph share verified history with the Genialis team — schools, employers, funds. One of them is your warm intro.
Ryan Haysunlockedknows Rafael Rosengarten · together at Dartmouth College (overlapped)
knows the team · via Baylor College of Medicine
×8knows the team · via Yale University
knows the team · via Dartmouth College
knows the team · via Joint BioEnergy Institute
Genialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
Founders & leadership
Genialis was founded in 2015 by Miha Štajdohar, Rafael Rosengarten, and Luka Ausec.
MŠ
Miha ŠtajdoharinCo-founder · Chief Technology OfficerMiha Štajdohar is founder and CTO of Genialis, which develops RNA biomarkers and machine learning tools to support precision oncology and patient stratification in cancer drug development. He has a background in AI and contributed to open-source and open-science initiatives.
RR
Rafael RosengarteninCo-founder · Chief Executive OfficerRafael Rosengarten is CEO and co-founder of Genialis, a precision oncology company applying data analysis to cancer drug development. He holds a doctorate from Yale University and completed postdoctoral training in synthetic biology at Lawrence Berkeley National Laboratory, followed by a National Library of Medicine fellowship in biomedical informatics at Baylor College of Medicine.
LA
Luka AusecinCo-founder · Chief Discovery Officer at GenialisChief Discovery Officer at Genialis, a precision oncology company applying RNA biomarker analysis to advance drug development. Ausec holds a Ph.D. in molecular biology and biotechnology from the University of Ljubljana.
HA
Hamzeh Abdul-HadiNamed on SEC filing
TK
Tjasa Krisper KutinNamed on SEC filing
Board
Investors · 6
Reported raises · per SEC filings
Form D private placements$12.1M disclosed across 2 rounds · 2023–2025
▶$700KraisedDec 2025 · 2 investors · BiotechnologyRule 506(b)
▶$700KraisedDec 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ita LuDirector
- Cedric Hermann OdjeDirector
- Elia StupkaDirector
- Krista McKerracherDirector
- Miha StajdoharExecutive Officer, Director
- Rafael RosengartenExecutive Officer, Director
- Luka AusecExecutive Officer
- Offering amount
- $3M
- Amount sold
- $700K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.4MraisedJan 2023 · 10 investors · BiotechnologyRule 506(b)
▶$11.4MraisedJan 2023 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nadine GeiserDirector
- Elia StupkaDirector
- Ita LuDirector
- Luka AusecExecutive Officer
- Rafael RosengartenExecutive Officer, Director
- Hamzeh Abdul-HadiDirector
- Drew VolpeDirector
- Miha StajdoharExecutive Officer, Director
- Tjasa Krisper KutinExecutive Officer
- Offering amount
- $13.9M
- Amount sold
- $11.4M
- Proceeds to insiders
- $1.4M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Zentalis16 shared keywordsZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Thumbnail for Seragon Pharmaceuticals13 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Gradalis12 shared keywordsGradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
Fortis Life Sciences11 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Genialis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Genialis do?
- Genialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
- Who founded Genialis?
- Genialis was founded by Miha Štajdohar, Rafael Rosengarten, Luka Ausec in 2015.
- Who are Genialis's investors?
- Genialis's investors include Angelini Ventures, Taiwania Capital, Debiopharm Innovation Fund, First Star Ventures, ScaleX Ventures, redalpine.
- How much funding has Genialis raised?
- Genialis has disclosed $12.1M raised across 2 rounds.
- Where is Genialis headquartered?
- Genialis is headquartered in Boston, US.